Site-specific cancer incidence by race and immigration status in Canada 2006-2015: a population-based data linkage study

Talía Malagón¹, Samantha Morais¹, Parker Tope¹, Mariam El-Zein¹, Eduardo L Franco¹

1. Division of Cancer Epidemiology, Department of Oncology, McGill University, Montréal, Canada

Correspondence:

Talía Malagón, PhD
Division of Cancer Epidemiology
Department of Oncology
McGill University
5100 Blvd de Maisonneuve W, Suite 720
Montréal, QC H4A 3T2
CANADA
514-398-5984
talia.malagon@mcgill.ca

Running title: Cancer incidence by race and immigration in Canada

Keywords: Cancer incidence, Racial groups, Immigrants, Data Linkage, Canada

Abstract

Introduction

The Canadian Cancer Registry does not collect demographic data beyond age and sex, making it hard to monitor health inequalities in cancer incidence in Canada, a country with public healthcare and many immigrants. Using data linkage, we compared site-specific cancer incidence rates by race.

Methods

We used data from the 2006 and 2011 Canadian Census Health and Environment Cohorts (CanCHECs), which are population-based probabilistically linked datasets of 5.9 million respondents of the 2006 Canadian long-form census and 6.5 million respondents of the 2011 National Household Survey. Respondents' race was self-reported using Indigenous identity and visible minority group identity questions. Respondent data were linked with the Canadian Cancer Registry up to 2015. We calculated age-standardized incidence rate ratios (ASIRR), comparing group-specific rates to the overall population rate with bootstrapped 95% confidence intervals (95%CI). We used negative binomial regressions to adjust rates for socioeconomic variables and assess interactions with immigration status.

Results

The age-standardized cancer incidence rate was lower in almost all non-White racial groups than in White individuals, except for Indigenous peoples who had a similar overall age-standardized cancer incidence rate (ASIRR 0.99, 95%CI 0.97-1.01). Immigrants had substantially lower age-standardized overall cancer incidence rates than non-immigrants (ASIRR 0.83, 95%CI 0.82-0.84). Non-White racial groups generally had significantly lower or equivalent site-specific cancer incidence rates than the overall population, except for stomach, liver, and thyroid cancers and for multiple myeloma. Differences in incidence rates by race persisted even after adjusting for household income, education, and rural residence, with immigration status being an important modifier of cancer risk.

Conclusions

Differences in cancer incidence between racial groups are likely influenced by differences in lifestyles and early life exposures, as well as selection factors for immigration. This suggests a strong role of environment in determining cancer risk and further potential for cancer prevention.

Introduction

The collection of race-based and Indigenous identity data is essential to measure and address health inequalities. Most evidence regarding racial inequalities in cancer health outcomes comes from the United States; 1,2 however, findings from the United States may not be transposable to other health systems with different populations and contextual factors influencing health. The examination of race-based outcomes in other countries can help to identify commonalities and potential differences in drivers of cancer inequalities.

Canada is a country with a public healthcare system and universal health coverage. It is ethnically and racially diverse with a large proportion of immigrants. While evidence exists that cancer screening, incidence, and survival differ by race and ethnicity in Canada, 3-7 recent national-level estimates of sitespecific cancer incidence by race are lacking. The Canadian Cancer Registry does not collect demographic data beyond age and sex, making it difficult to monitor inequalities in cancer incidence and mortality across Canada. There is a legacy of colonialism and a historical reluctance to gather race-based data in Canada, which have led to a current paucity of data for monitoring racial health inequalities.^{8,9} There have been recent calls to provide more racially disaggregated health data. For historical and legal reasons, race data is often collected by Canadian institutions using the controversial 10 construct of 'visible minority group', defined as persons, other than Indigenous peoples, who are non-Caucasian in race or non-white in colour. In 2022 the Canadian Institute of Health Information (CIHI) published updated guidance on the use of standards for race-based and Indigenous identity data health reporting, dropping the term 'visible minority'. 11 These standards distinguish between race and ethnicity, with race defined as a social construct used to categorize people based on perceived differences in physical appearance, and ethnicity defined as a multi-dimensional construct based on community belonging and a shared cultural group membership. This definition of race subsumes the construct of visible minority by including White and Indigenous populations. However, because much of the data collected in Canada still uses visible minority group definitions, in this paper we use the term race when referring to all racial groups and the term visible minority groups when referring specifically to racial groups who are not White and not Indigenous.

Due to the low incidence rate of some cancers, large data-linkage studies are required to monitor racial inequalities for many cancers in Canada. Our objective was to measure differences in site-specific cancer incidence across racial groups in a representative Canadian population to identify inequalities in cancer incidence. We also assessed whether socioeconomic status and immigration contribute to differences in cancer incidence by race.

Methods

Study sample and data sources

The study sample includes members of the 2006 and 2011 Canadian Census Health and Environment Cohorts (CanCHECs), a set of population-based probabilistically linked datasets based on the long-form census and the National Household Survey (NHS). The 2006 long-form census questionnaire was a mandatory questionnaire sent to approximately one in five Canadian households collecting information on relationships, languages, labour, income, education, housing, immigration, race, and ethnic origin. The long-form census was replaced with the NHS in 2011, a voluntary survey collecting the same information as the long-form census sent to approximately one in three Canadian households. Health

surveys targeted the non-institutionalized usual residents of Canada on Census Day (mid-May 2006 or 2011), including both permanent and non-permanent residents. Survey respondents were probabilistically linked using personal identifiers to the Derived Record Depository (DRD), a national dynamic relational database of individuals residing in Canada. The 2006 and 2011 CanCHEC cohorts include the 90.8% of the 2006 long-form census respondents and 96.7% of 2011 NHS respondents who could be linked to the DRD. The properties of Canada and Page 12006 and 2011 CanCHEC cohorts are properties of the 2006 long-form census respondents and 96.7% of 2011 NHS respondents who could be linked to the DRD.

Cohort records were linked via the DRD up to December 31st 2015 to the Canadian Vital Statistics Death Database (CVSD)¹⁶, the Canadian Cancer Registry (CCR)¹⁷, and the annual postal codes file¹⁸. The CVSD collects dates and cause of death information annually from all provincial and territorial vital statistics registries on all deaths in Canada. The CCR is a population-based registry that includes information about each new primary cancer diagnosed in Canada. The International Agency for Research on Cancer (IARC) rules were used for determining multiple primary cancers in the CCR.¹⁹ Cancers were grouped by site using Surveillance, Epidemiology, and End Results (SEER) site groupings based on ICD-O-3 codes (Supplementary Table 1). For head and neck cancers, we used the definition used by the 2021 Canadian Cancer Statistics.²⁰

The annual postal code file collects the mailing addresses provided on income tax returns by tax filers. Postal codes were used to estimate changes in a person's place of residence for each year of follow-up after the census year (2006 or 2011). For individuals in the CCR or CVSD, we used the residential postal code available in these registries instead of the annual postal code file for the years in which they were diagnosed with cancer or died. The geographical information related to each postal code was extracted using the Postal Code Conversion File Plus program version 7D.²¹ Postal codes were not available for all cohort members or for all follow-up years due to missing tax records or census respondents who did not give permission to link tax returns. For years with missing postal code data, we imputed the last known place of residence from the CCR, annual postal code file, long-form census/NHS (in order of priority) forward to subsequent years.

Racial group & immigrant status

Racial identity and immigrant status were self-reported based on the Aboriginal group, visible minority group, immigrant status, and citizenship questions in the long-form census (2006) and the NHS (2011).^{22,23} The racial categories in these questions are based on the visible minority group definitions used for federal employment equity programs in Canada. The visible minority group question was directed to respondents who did not identify as Indigenous, and included 11 response categories (White, South Asian, Chinese, Black, Filipino, Latin American, Arab, Southeast Asian, West Asian, Korean, and Japanese) and a write-in space. Respondents who reported belonging only to a single group were included in that corresponding racial group category. Respondents who selected multiple groups were classified using rules used by employment equity definitions.²² Respondents who reported being both 'White' and 'Chinese', 'South Asian', 'Black', 'Filipino', 'Southeast Asian', 'Japanese', or 'Korean' were included in their corresponding visible minority group category. Respondents who reported being both 'White' and 'Latin American', 'Arab', or 'West Asian' were included in the 'White' category, as these are not considered to be visible minority groups by employment equity definitions and are grouped with 'White' in survey data products. Respondents who reported belonging to multiple non-White visible minority groups were categorized as 'Multiple visible minority groups'. Those who provided a write-in response not classifiable into any other group were categorized as 'Other visible minority groups'.

Native-born Canadians (non-immigrants) are those who indicated they were born in Canada; immigrants are those born outside of Canada who have been granted the right to live in Canada permanently by immigration authorities; and non-permanent residents are those who are neither born in Canada nor immigrants (ex. person with a temporary work/study permit).

Statistical analyses

The 2006 and 2011 CanCHECs were pooled together to increase the sample size and statistical power for the analysis. Respondents contributed person-time at risk and events from the year of their survey response (2006 or 2011) up to their year of death or December 31st 2015. Because the province of Québec has not reported new cancer cases to the CCR since 2010, we excluded person-time from Québec residents after 2010. To calculate person-time and events by age, we used each person's age at the midpoint of each calendar year (July 1st) of follow-up.

We calculated age-standardized cancer incidence rates and age-standardized incidence rate ratios (ASIRR) by population group using the 2011 Canadian population age distribution as standard.²⁴ Age-specific incidence rates were weighted by CanCHECs survey weights in order to be representative of the Canadian population living in private dwellings. The CanCHECs survey weights are calibrated to account for survey sampling probability, non-response rates, and DRD linkage probabilities.¹² The 95% confidence intervals (CI) for age-standardized cancer incidence rates and ASIRR were calculated through bootstrapping, using the 2.5th and 97.5th percentile intervals of 500 bootstrap replicate weights developed for the CanCHECs. To validate sample representativeness, we compared cancer incidence rates in the CanCHECs with national cancer incidence rates reported during the same period; the results were highly similar (Supplementary Tables 2-3). In secondary analyses, we also age-standardized using the 1960 World Population for comparisons with cancer incidence rates in the world region of origin of visible minority groups using GLOBOCAN 2020 data.^{25,26}

To assess whether incidence rate ratios between racial groups could be attributed to a healthy immigrant effect or differences in socioeconomic status, we used negative binomial regression models. Regression models used the logarithm of group person-years at risk as an offset. These regression models included an interaction term between race and immigration status to calculate different rates for native-born Canadians compared with foreign-born immigrants and non-permanent residents. Incidence rates were adjusted for 5-year age group, sex, calendar year, province of residence, rural/urban place of residence, education level, and quintiles of household after-tax income adjusted for household size. Due to the small numbers of events in some racial groups when assessing interactions with immigration, some populations were grouped together in regression analyses to improve model stability while maintaining meaningful distinctions for race-based reporting: Chinese, Filipino, Southeast Asian, Korean, and Japanese were grouped as East/Southeast Asian; West Asian and Arab were grouped as Middle Eastern; and those in multiple visible minority groups were combined with the other visible minority groups category.

Ethics and confidentiality

We obtained ethical approval from the McGill University Institutional Review Board for this analysis of secondary data. To protect respondent confidentiality, analysis outputs were vetted using rules developed by Statistics Canada, which include rounding of all counts to the nearest 5 and not disclosing descriptive statistics for groups with less than 5 events. In analyses where the number of cancer cases in

a racial group did not meet the disclosure threshold, we either combined this group with the 'Other visible minority group' or suppressed outputs as indicated.

Results

There were 5.9 million respondents in the 2006 CanCHEC and 6.5 million respondents in the 2011 CanCHEC (Table 1). The most common racial groups in both cohorts were White (75-78%), Indigenous peoples (7-8%), South Asian (4-5%), and Chinese (3-4%) populations. Immigrants constituted 18-20% of respondents and non-permanent residents 1% of respondents. The proportion of immigrants and non-permanent residents was substantially higher among visible minority groups than among White individuals and Indigenous peoples. The median time since immigration for immigrants was 18 years (interquartile range 8-36).

Age-standardized cancer incidence rates by race, sex, and immigration status for all cancer sites combined are presented in Table 2 and Figure 1. Age-standardized cancer incidence rates were lower in nearly all non-White racial groups than in White individuals, except for Indigenous peoples who had a similar overall age-standardized cancer incidence rate (ASIRR 0.99, 95%CI 0.97-1.01). Overall, women had a lower age-standardized overall cancer incidence rate than men (ASIRR 0.83, 95%CI 0.82-0.83), but the female to male cancer ASIRR displayed substantial variation by racial group. Immigrants had substantially lower age-standardized overall cancer incidence rates than native-born Canadians (ASIRR 0.83, 95%CI 0.82-0.84). The ASIRR between immigrant and native-born Canadians also displayed substantial variation by racial group.

Site-specific age-standardized incidence rates and ASIRRs are presented in Table 3 and Table 4, respectively. White individuals had higher age-standardized incidence rates than the overall population across most sites, with the notable exceptions of stomach, liver, and thyroid cancers, and multiple myelomas. With these cancers excepted, visible minority groups generally had lower or equivalent age-standardized cancer incidence rates compared to the overall population. Indigenous peoples had higher incidence rates for certain cancer sites (head and neck, stomach, colorectal, liver, pancreas, lung and bronchus, cervical, kidney and renal pelvis) but lower incidence rates for other cancer sites (melanoma, uterus, prostate, testis, bladder, brain and central nervous system, thyroid, Hodgkin Lymphoma, and leukemia) compared to the overall population.

Differences in most cancer incidence rates between racial groups persisted even after adjustment for age, sex, year, province, place of residence, education level, and household income in regression models (Table 5). Stratification by immigration status further revealed relationships with immigration which differed by site. For most cancer sites, the cancer incidence rates showed a trend of convergence, where native-born members of racial groups had closer incidence rates to the native-born White individuals than foreign-born members of racial groups. This was not the case for all cancer sites, however: stomach, cervical, thyroid cancer, and multiple myeloma incidence rates were in most cases equivalent between foreign-born and native-born racial groups.

Age-standardized incidence rates by visible minority groups compared with GLOBOCAN 2020 incidence estimates by world regions of origin are provided in Supplementary Table 4 and Supplementary Figures 1-24. For most cancer sites, incidence rates tended to be intermediate between the rates in White Canadians and the rates from their world region of origin. However, for head and neck, lung and bronchus, esophageal, pancreatic, and cervical cancers, the incidence rates in visible minority groups

were markedly lower than in both White Canadians and their world region of origin. For thyroid cancer, the incidence rates in visible minority groups were strikingly higher than in both White Canadians and their world region of origin.

Discussion

This study estimated cancer incidence rates by race using a very large representative population-based sample of the Canadian population linked to a cancer registry with national coverage. Because the CCR does not collect data on race, our results are to our knowledge the most nationally representative up-to-date estimates of cancer incidence rates stratified by race in Canada. We found that for most cancer sites, non-White and non-Indigenous racial groups had lower age-standardized cancer incidence rates than the overall population. Indigenous peoples had higher age-standardized incidence rates for some cancer sites but lower for others compared with the overall population. Differences in cancer rates between racial groups remained even after adjusting for differences in socioeconomic status. However, immigration status was an important modifier of cancer risk, suggesting that a healthy immigrant effect influences cancer risk by race in Canada.

Inequalities in cancer incidence are influenced by the social determinants of health. ^{9,27} Individuals who are more resourced are in general better able to adopt healthy lifestyles and avail themselves of preventive healthcare. ²⁸ Though Canada has a public healthcare system with universal health coverage available for all citizens and permanent residents, there is a socioeconomic gradient in cancer risk across multiple sites. ²⁹⁻³² Nevertheless, our analysis suggests that differences in household income, education, and urbanicity are not the fundamental causes of the observed differences in cancer incidence observed between racial groups, as incidence differences persisted despite adjustment for these variables. Systemic racism and enduring colonial influences on Indigenous peoples' health contribute to health inequalities between racial groups. ³³ However, the observed patterns suggest that differences between racial groups are also likely linked to lifestyles, culture, early life exposures, and selection factors for immigration.

Immigration was an important modifier of cancer risk. Most immigrants to Canada are economic immigrants selected based on their ability to contribute to labour market needs.³⁴ Immigrants applying for permanent residency must undergo a medical examination. Applicants may be found inadmissible for residency if they present medical conditions deemed to potentially cause excessive demands on health and social services. There is therefore a strong selection for immigrants in better health than native-born Canadians, known as the healthy immigrant effect.^{35,36} We hypothesize that cancer rates would be intermediate between the world region of origin and those in native-born Canadians for cancer sites where adult lifestyles are important risk factors such as obesity, diet, and occupational exposures. We found that this was the case for many cancer sites such as colorectal, breast, uterus (corpus), prostate, kidney and renal pelvis, non-Hodgkin lymphoma, and leukemia. However, for many other sites the cancer incidence rate in racial groups was lower than in both native-born Canadians and their world region of origin. This was the case for head and neck, esophagus, lung and bronchus, and cervical cancers. These cancers are strongly related to exposures adopted early in life prior to immigration and linked with socioeconomic status: tobacco consumption, alcohol drinking, and early life infections. 37,38 The low incidence rates for these cancers suggest there is a selection for immigrants in better health and from higher socioeconomic backgrounds from within their country of origin, who are less likely to be smokers³⁶ and heavy drinkers,³⁹ and exposed to some infections. The high rates of

cervical cancer in Indigenous women are attributable to both higher human papillomavirus (HPV) infection prevalence and lower screening coverage; 40-43 however we are unaware of any studies comparing HPV prevalence by immigrant status or other racial groups in Canada. Immigrant and racialized women are nonetheless known to have lower cervical cancer screening rates, 5,44 suggesting that the lower risk of cervical cancer in many visible minority groups cannot be attributed to more screening and is likely in part due to a lower prevalence of HPV. Lastly, for some cancer sites the cancer incidence rates were higher in some racial groups than in both White native-born Canadians and their world region of origin, notably for prostate (Black men) and thyroid cancers, and for multiple myeloma (some groups). As these cancers are often diagnosed through incidental findings, this pattern potentially signals underdiagnosis of these cancers in some world regions, and more incidental diagnoses in Canada during examinations for other health problems.

Stomach, liver, and thyroid stood out as the cancer sites where incidence rates were systematically higher across most racial groups than in White individuals. It is likely that for stomach and liver cancers, the higher incidence rates reflect childhood exposures to Helicobacter pylori and hepatitis B virus in the countries of origin of many immigrants, 45,46 as well as higher prevalences of H. pylori and hepatitis C virus in some Indigenous populations. 46-48 Remarkably, the rates of these cancers were also high in Canadian-born East Asian, Southeast Asian, and Middle Eastern individuals. It is possible that the persisting high rates of these cancers in native-born Canadians of these racial groups are due to vertical or familial transmission of these pathogens. While all provinces perform prenatal screening for hepatitis B to provide vaccination against hepatitis B to at-risk children, prenatal hepatitis B screening and followup has imperfect coverage. ⁴⁹ There is no routine screening for *H. pylori* in Canada. The risk of stomach cancer does not appear to decline with time since immigration in many Canadian immigrant groups.⁵⁰ While H. pylori prevalence tends to decrease in successive generations of immigrants, it still often remains higher than the prevalence of the native host country population.⁵¹ Persistence of stomach cancer risk across generations may also reflect conserved cultural differences in diet, such as consumption of foods high in salt.⁵² For thyroid cancer, more incidental cancer diagnoses in the Canadian healthcare system likely account for the higher rates of this cancer in visible minority groups compared with their world regions of origin. However, it is not clear why rates are higher in visible minority groups than in White Canadians and Indigenous peoples. This finding is in stark contrast with the United States, where thyroid cancer incidence rates are highest in White populations and lowest in Black populations due to racial disparities in access to healthcare.⁵³ Non-White racial groups are less likely to use cancer screening services and just as likely to have contact with specialist physicians as White Canadians, ⁵⁴ so the higher thyroid cancer rates are not plausibly explained by more incidental findings in visible minority groups.

An important limitation of our analysis is that we are unable to account for emigration; it is therefore possible we may have underestimated cancer incidence rates due to the inclusion of person-time from cohort members who have left Canada. Emigration is likely higher for non-permanent residents. Cancer incidence might therefore be more underestimated in groups with more non-permanent residents, such as Korean and Latin American populations. Cancer incidence may also be underestimated due to the exclusion from CanCHECs of homeless or institutionalized populations living in nursing homes and penitentiaries, who are likely to be in poorer health. However, we compared CanCHECs cancer incidence rates with the national incidence rates (which are not subject to these biases) and found very similar rates. This suggests that this underestimation is likely to be minimal overall. We aimed to provide as

disaggregated data as possible for racial categories, in alignment with calls for disaggregated health data by race. ^{1,8} However, this disaggregation came at the cost of lower statistical power for some cancer sites to detect meaningful differences. Even by pooling two CanCHECs with several years of follow-up, we were unable to meet confidentiality disclosure thresholds for rarer cancers in some racial groups.

While previous studies have examined racial and ethnic differences in cancer rates in Canada, they have tended to be based in a single province or examined only the most frequent cancer types. Much previous research has focused on cancer in Indigenous peoples, 6,40,55,56 with much less research on other racial groups. A study of the 1991 CanCHEC established the existence of a healthy immigrant effect for cancer incidence rates by immigration status.3 It is often assumed that cancer rates in immigrants will trend towards those in their host country with time since immigration due to acculturation. However, that study and others³⁵ found that the convergence of cancer incidence rates and mortality rates between immigrants and non-immigrants over years since arrival might be partly explained by changes in the countries of origin of immigrants over time, as more recent immigrants have come from world regions with lower cancer rates. These findings suggest that either immigrant lifestyles might not assimilate as much as previously believed, or that lifestyle changes later in adulthood may be less important for cancer risk and point to a potentially important role of early life exposures. For example, the proportion of overweight immigrants does not greatly increase with time since immigration, and remains lower than in Canadian-born individuals even a decade after immigration.³⁶ While there are few studies of dietary acculturation in Canada, some studies suggest that many immigrants maintain their traditional diet to a certain extent.^{36,57} If culture and lifestyle are conserved across generations, this may explain why we found that cancer incidence did not fully converge between Canadian-born visible minorities and those not identifying as visible minorities. A previous study of the 2006 CanCHEC estimated differences in overall cancer incidence rates by ethnicity and immigration status, but did not estimate site-specific cancer incidence rates as we have done. That study also examined the construct of ethnicity rather than race, using the ethnic origin census question rather than the Indigenous group and visible minority group questions. While there is construct overlap, a person's ethnic origin may not necessarily correspond with their race. We opted to use the constructs of visible minority group combined with Indigenous identity to capture race rather than ethnicity, and to align more closely with race-based and Indigenous identity data standards for measuring racial health inequities in Canada. 11

Cancer is a heterogenous group of diseases with different aetiologies and long latency. We focus the discussion above on large trends across sites; however, an understanding of the drivers of cancer inequalities requires a separate analysis by cancer site and over time to account for changes in risk after adoption of a new home country. Lastly, the large differences we have observed between racial groups point to important potential gains in cancer prevention. The ComPARe study estimated that 33-37% of cancers among adults in Canada are attributable to preventable risk factors such as tobacco consumption. However, the differences we observed between racial groups are in some cases larger than the estimated preventable fractions of some cancer sites. This suggests that the preventable fraction of cancer from environment and lifestyle may still be underestimated. More studies of immigrant and racial group lifestyles and experiences may further elucidate opportunities for cancer prevention.

Conflicts of interest

TM, SM, and PT have no conflicts of interest to declare. ELF reports grants to his institution from the Canadian Institutes of Health Research, the National Institutes of Health, and Merck during the conduct of the study; and personal fees from Merck. MZ and ELF hold a patent related to the discovery "DNA methylation markers for early detection of cervical cancer", registered at the Office of Innovation and Partnerships, McGill University, Montréal, Québec, Canada.

Funding

This study was funded by a Canadian Institutes of Health Research (CIHR) (grant 179901) to EF, and by a CIHR HIV/AIDS and STBBI Research Initiative, sponsored by the CIHR Institute of Infection and Immunity, Postdoctoral Fellowship Award (support to SM; Funding Reference Number: 202110HIV-477526-93701).

Acknowledgement

Data Source: Statistics Canada, Canadian Census Health and Environment Cohorts 2006 & 2011, 2006 long-form census, 2011 National Household Survey, Canadian Vital Statistics Death Database 2006-2015, and Canadian Cancer Registry 2006-2015. The Postal Code^{OM} Conversion File Plus (7D) is based on data licensed from Canada Post Corporation. Reproduced and distributed on an "as is" basis with the permission of Statistics Canada. This does not constitute an endorsement by Statistics Canada of this product.

Data availability

Statistics Canada is the owner and steward of the data used in this report, and access to the data is regulated by the 1985 *Statistics Act*. To access the data, researchers must become deemed employees of Statistics Canada and sign a research contract. Members of post-secondary institutions such as a faculty, students, or staff may apply for data access to Statistics Canada microdata through the Research Data Centre program using the Microdata Access Portal (https://www.statcan.gc.ca/en/microdata/data-centres/access). Code used for the current analyses is available at the Borealis repository, at https://doi.org/10.5683/SP3/Z8RBON.

Figures




Figure 1. Age-standardized incidence rate of cancer per 100,000 person-years by sex and race, all cancer sites combined. Age-standardized to the 2011 Canadian census population. Source: Adapted from Statistics Canada, Canadian Census Health and Environment Cohorts 2006 & 2011, 2006 long-form census, 2011 National Household Survey, Canadian Vital Statistics Death Database 2006-2015, and the Canadian Cancer Registry 2006-2015.

Tables
Table 1 Baseline characteristics of 2006 and 2011 CanCHECs by race.

					2006 Can	CHEC								2011 Can	CHEC			
								Median									Median	
							Non-	years								Non-	years	
							permane	since								permane	since	
				Median			nt	immi-					Median			nt	immi-	
			Female	age^b		Immigra	resident	gration				Female	age^b		Immigra	resident	gration	
Racial group	N^a	%	(%)	(years)	(IQR)	nt (%)	(%)	b,c	(IQR)	N ^a	%	(%)	(years)	(IQR)	nt (%)	(%)	b,c	(IQR)
White	4,577,410	78	51	41	(21-56)	11	<1	34	(16-47)	4,871,965	75	51	43	(22-58)	11	<1	35	(15-47)
Indigenous peoples	442,515	8	50	25	(12-43)	1	<1	21	(8-32)	460,880	7	51	26	(12-45)	<1	<1	25	(9-38)
Chinese	202,410	3	52	37	(20-51)	71	2	13	(7-22)	277,300	4	52	39	(21-53)	70	2	15	(8-23)
Korean	20,970	<1	50	33	(18-47)	74	9	8	(4-17)	30,080	<1	52	35	(18-49	74	8	10	(6-19)
Japanese	13,765	<1	55	37	(21-56)	27	6	14	(6-31)	16,770	<1	56	37	(19-55)	29	4	14	(6-31)
Filipino	70,580	1	57	35	(17-48)	71	4	12	(5-19)	112,155	2	56	34	(17-48)	70	6	11	(4-20)
Southeast Asian	38,765	1	51	32	(16-46)	66	2	17.5	(12-24)	53,375	1	51	34	(18-49)	63	2	21	(12-29)
South Asian	216,675	4	50	31	(15-47)	69	2	11	(5-20)	292,585	5	50	33	(16-48)	68	2	13	(6-22)
West Asian	25,790	<1	49	32	(18-46)	82	3	8	(4-15)	35,425	1	49	33	(19-48)	81	3	10	(5-17)
Arab	44,865	1	46	30	(14-43)	69	3	10	(4-16)	70,290	1	47	30	(13-44)	70	3	10	(4-19)
Black	130,645	2	52	29	(13-44)	52	3	15	(7-29)	155,895	2	52	29	(13-45)	54	3	15	(6-29)
Latin American	51,365	1	50	32	(18-45)	72	8	14	(5-20)	70,325	1	52	34	(19-46)	74	6	12	(5-22)
Multiple visible minority groups ^d	23,270	<1	51	24	(10-42)	49	1	17	(9-27)	33,920	1	52	24	(10-44)	47	2	18	(8-29)
Other visible minority groups ^e	12,315	<1	52	33	(18-47)	63	2	17	(10-28)	18,225	<1	53	33	(16-49)	58	1	19	(9-31)
Total	5,871,335	100	51	39	(19-54)	18	1	18	(8-36)	6,499,185	100	51	40	(20-56)	20	1	18	(8-36)

Source: Adapted from Statistics Canada, Canadian Census Health and Environment Cohorts 2006 & 2011, 2006 long-form census, and 2011 National Household Survey. CanCHECs=Canadian Census Health and Environment Cohorts; IQR=Interquartile range.

^a Counts are rounded to base 5.

^b Measured at baseline.

^c Immigrants excluding non-permanent residents.

^d Most reported write-in answers to the ethnic group question in this category: Canadian, Chinese, East Indian, Filipino, Vietnamese.

^e Most reported write-in answers to the ethnic group question in this category: Canadian, Guyanese, Trinidad and Togabo, East Indian, West Indian.

Table 2. Age-standardized cancer incidence rate for all sites combined per 100,000 person-years and incidence rate ratios by race, age-standardized to the Canadian 2011 census population.

		A	Age-standardi:	ed cancer i	ncidence rates (/	100,000 person	-years)		Age-s	standardized ind	cidence rate rat	ios	
							Non-permanent	Racial group vs.		Females vs.		Immigrants vs.	
Racial group	Events ^a	Overall	Females	Males	Native-born	Immigrants	residents	White	(95% CI)	males	(95% CI)	Native-born	(95% CI)
Overall	411,220	514	471	570	542	450	392	-	-	0.83	(0.82-0.83)	0.83	(0.82-0.84)
White	355,555	536	488	599	544	512	447	(Reference)	-	0.81	(0.81-0.82)	0.94	(0.93-0.95)
Indigenous peoples	17,950	529	507	559	530	472	730	0.99	(0.97-1.01)	0.91	(0.86-0.95)	0.89	(0.70-1.11)
Chinese	11,455	360	361	360	392	358	308	0.67	(0.66-0.68)	1.00	(0.96-1.05)	0.91	(0.83-1.02)
Korean	950	342	319	367	516	341	337	0.64	(0.58-0.69)	0.87	(0.74-1.01)	0.66	(0.42-1.47)
Japanese	975	413	426	394	408	404	218	0.77	(0.72-0.83)	1.08	(0.93-1.25)	0.99	(0.85-1.17)
Filipino	3,915	407	402	425	439	407	334	0.76	(0.73-0.79)	0.94	(0.88-1.04)	0.93	(0.63-1.34)
Southeast Asian	1,290	326	310	352	451	319	300	0.61	(0.57-0.65)	0.88	(0.77-1.03)	0.71	(0.51-1.08)
South Asian	8,195	297	308	289	394	294	200	0.55	(0.54-0.57)	1.06	(1.01-1.12)	0.74	(0.59-0.95)
West Asian	1,090	379	343	415	644	374	250	0.71	(0.65-0.75)	0.83	(0.73-0.96)	0.58	(0.38-1.00)
Arab	1,480	445	442	450	626	432	625	0.83	(0.77-0.89)	0.98	(0.86-1.12)	0.69	(0.53-0.91)
Black	5,225	451	373	552	588	434	420	0.84	(0.81-0.87)	0.68	(0.63-0.73)	0.74	(0.67-0.82)
Latin American	1,615	353	331	390	436	353	309	0.66	(0.61-0.70)	0.85	(0.74-0.97)	0.81	(0.54-1.37)
Multiple visible minority	905	416	422	416	574	403	477	0.78	(0.72 - 0.84)	1.01	(0.86-1.20)	0.70	(0.49-1.04)
groups													
Other visible minority groups	625	397	371	447	404	398	194	0.74	(0.67-0.82)	0.83	(0.66-0.99)	0.99	(0.61-2.18)

95% Cl=confidence intervals based on 2.5th and 97.5th bootstrap percentiles

^a Counts are rounded to base 5.

Table 3. Age-standardized cancer incidence rates per 100,000 person-years by cancer site and race, age-standardized to the Canadian 2011 census population.

		Age-standardized cancer incidence rates /100,000 person-years (95% CI) Multiple Other														
Cancer site	Total number of events ^a	Overall	White	Indigenous peoples	Chinese	Korean	Japanese	Filipino	Southeast Asian	South Asian	West Asian	Arab	Black	Latin American	Multiple visible minority groups	Other visible minority groups ^b
All cancers	411,220	514	536	529	360	342	413	407	326	297	379	445	451	353	416	397
	,	(512-516)	(534-538)	(518-544)	(352-367)	(313-371)	(385-445)	(392-422)	(303-350)	(289-304)	(348-404)	(415-475)	(434-464)	(329-374)	(384-451)	(360-441)
Head and neck	12,315	15.4	16.1	18.6	12.2	2.6	8.7	10.6	7.4	10.9	9.6	6.6	6.6	8.0	13.2	11.9
		(15.0-15.7)	(15.7-16.5)	(16.5-20.9)	(10.9-13.5)	(0.8-4.6)	(4.7-13.1)	(8.1-12.8)	(4.0-10.3)	(9.5-12.5)	(6.2-13.4)	(3.9-9.8)	(4.7-8.6)	(5.1-12.1)	(6.7-19.0)	(6.0-18.6)
Esophagus	4,125	5.2	5.7	6.1	1.8	С	5.8	0.9	С	3.1	2.4	С	2.8	0.9	С	1.6
		(5.0-5.4)	(5.4-5.9)	(4.8-7.4)	(1.2-2.2)		(2.0-8.1)	(0.3-1.6)		(2.3-4.1)	(0.6-4.4)		(1.5-4.3)	(0.2-1.6)		(0.7-2.5)
Stomach	7,435	9.3	9.0	11.1	10.7	30.6	26.1	6.9	11	5.9	9.9	14.5	12	17.4	9.9	10.9
		(9.0-9.5)	(8.7-9.3)	(9.4-12.9)	(9.4-11.9)	(23.8-37.5)	(18.0-35.0)	(4.8-9.2)	(7.2-15.0)	(4.7-7.2)	(5.3-14.8)	(9.4-19.8)	(9.3-14.3)	(12.3-22.7)	(5.3-14.8)	(5.8-16.3)
Colorectal	50,595	62.4	64.9	79.6	50	41.2	68.2	47.4	43.1	26.5	39.7	47.4	44.3	36.5	51.9	44.5
		(61.8-63.0)	(64.1-65.5)	(75.0-85.0)	(47.0-53.0)	(33.0-51.1)	(58.3-81.0)	(42.2-53.9)	(35.0-51.4)	(24.2-28.5)	(29.5-48.9)	(37.9-57.3)	(39.7-48.9)	(29.8-43.6)	(40.9-64.2)	(33.5-56.9)
Anal	1,440	1.8	2.0	1.9	0.3	С	С	1.2	С	0.7	С	С	1.6	С	С	0.7
		(1.7-2.0)	(1.9-2.2)	(1.1-2.7)	(0.1-0.5)			(0.4-2.0)		(0.3-1.2)			(0.9-2.5)			(0.4-1.0)
Liver	4,095	5.1	4.4	11.0	12.9	14.7	5.1	7.4	20.2	4.7	2.6	4.5	5.1	7.0	13.4	4.3
		(4.9-5.3)	(4.2-4.6)	(8.9-13.3)	(11.5-14.4)	(10.0-20.3)	(1.9-8.5)	(5.5-9.4)	(15.0-25.5)	(3.7-5.7)	(1.0-4.3)	(2.2-7.1)	(3.8-6.6)	(4.0-10.2)	(7.6-19.7)	(1.7-7.7)
Pancreas	9,885	12.4	12.9	14.3	8.4	11.2	10.8	9.1	7.4	6.9	5.7	8.2	13.3	10.6	11.2	5.5
		(12.1-12.7)	(12.6-13.2)	(12.5-16.4)	(7.2-9.5)	(6.7-16.5)	(6.9-14.8)	(6.8-11.5)	(4.2-10.6)	(5.8-8.1)	(2.1-9.7)	(5.1-12.4)	(10.4-16.2)	(6.4-13.7)	(6.1-16.6)	(1.2-9.1)
Lung &	52,990	66.0	70.5	89.7	44.3	38.4	35.2	39.3	36.4	14.1	29.7	32.0	27.3	26.4	35.1	27.1
bronchus		(65.3-66.7)	(69.7-71.3)	(84.0-95.3)	(41.2-46.7)	(29.7-48.1)	(27.2-43.2)	(35.0-44.0)	(27.6-43.8)	(12.3-15.9)	(19.9-38.1)	(24.1-40.2)	(23.6-31.1)	(19.2-32.5)	(25.7-43.9)	(15.7-35.6)
Melanoma	15,400	19.3	22.9	6.6	1.2	C	C	0.9	2.0	1.1	1.6	4.6	3.3	5.7	2.1	1.2
Dunant (famala)	F2 140	(19.0-19.7)	(22.5-23.3)	(5.4-8.0) 126.6	(0.8-1.7)	02.0	142.0	(0.4-1.6)	(0.7-3.5) 75.3	(0.8-1.6)	(0.4-2.9)	(2.5-7.3) 134.1	(1.3-5.3)	(2.9-7.7) 87.5	(0.5-4.4) 142.7	(0.3-2.1)
Breast (female)	53,140	127.1	130.2		107.1	83.0 (68.4-	142.9 (123.9-	132		97.5	121.5	_	102.0			109.5
		(125.8- 128.4)	(128.6- 131.6)	(118.3- 134.8)	(101.4- 112.3)	100.8)	165.4)	(121.5- 140.2)	(62.3-91.1)	(92.3- 102.8)	(99.1- 138.3)	(113.7- 154.1)	(92.1- 111.6)	(72.8- 103.1)	(120.0- 166.5)	(85.9- 135.4)
Cervix (female)	3,045	7.4	7.7	12.0	4.8	6.3	6.9	8.2	11.5	4.9	130.3)	11.2	6.9	7.8	9.8	6.1
cervix (remaie)	3,043	7. 4 (7.1-7.7)	(7.4-8.1)	(10.3-13.6)	(3.7-5.9)	(3.0-10.2)	(2.8-12.0)	(5.3-10.4)	(7.1-16.3)	(3.6-6.4)		(1.1-18.6)	(4.7-9.4)	(4.6-11.9)	(4.1-15.9)	(2.1-9.8)
Uterus (female)	13,080	31	31.8	23.1	23.2	12.5	31.9	35.5	18.7	29.3	27.6	23.9	27.4	27.1	37.3	20.8
oterus (remaie)	13,000	(30.4-31.7)	(31.1-32.6)	(20.2-26.1)	(20.7-25.7)	(6.3-18.8)	(22.0-42.7)	(30.3-41.2)	(12.5-25.6)	(26.2-32.5)	(17.7-38.8)	(14.1-34.6)	(22.5-33.0)	(20.2-35.2)	(20.5-56.8)	(12.7-29.2)
Ovary (female)	6,000	14.2	14.4	13.5	11.2	5.1	22.7	10.1	15.9	15.2	14.2	13.9	11.6	14.6	10.9	18.5
o va. y (. o a. c)	0,000	(13.7-14.6)	(13.9-14.8)	(11.1-16.9)	(9.1-13.1)	(2.2-8.4)	(13.1-32.5)	(7.7-12.3)	(10.3-22.0)	(12.7-17.7)	(7.7-22.0)	(6.6-21.2)	(8.5-14.5)	(7.8-22.2)	(5.6-16.9)	(5.4-33.1)
Prostate (male)	52,840	138.5	143.6	114.4	82	76.2	113	123.2	71.1	79.4	118.4	97.1	264.6	111.2	130.2	129.8
	- ,	(137.3-	(142.2-	(106.9-	(77.3-87.5)	(58.3-95.2)	(92.5-	(108.0-	(55.6-87.9)	(73.4-84.3)	(96.9-	(79.6-	(247.2-	(95.5-	(103.9-	(101.7-
		140.0)	145.1)	123.5)			135.8)	136.7)	/		138.8)	114.4)	279.5)	128.8)	161.3)	163.7)
Testis (male)	2,120	5.9	6.9	4.6	2.1	С	c	1.2	С	3.3	5.8	4.2	1.9	4.4	2.3	1.3
, ,		(5.6-6.2)	(6.5-7.2)	(3.7-5.6)	(1.5-2.9)			(0.2-2.5)		(2.5-4.2)	(1.8-9.6)	(1.9-6.7)	(0.7-2.9)	(2.6-6.5)	(0.5-4.6)	(0.6-2.2)

Diaddau	10 225	24.0	20.1	100	٥٢	20.0	10 F	0.5	гэ	٥٢	10.0	20.2	10.2	0.0	0.0	12.2
Bladder	19,225	24.0	26.1	16.0	9.5	20.0	10.5	8.5	5.3	9.5	18.6	30.3	10.2	8.9	9.0	12.2
		(23.6-24.4)	(25.7-26.6)	(13.8-18.2)	(8.3-10.8)	(12.7-27.1)	(6.7-14.4)	(6.0-10.8)	(2.4-8.1)	(8.1-10.9)	(12.7-24.6)	(22.2-37.5)	(8.0-12.5)	(5.2-12.7)	(4.8-13.9)	(6.7-18.5)
Kidney & renal	12,490	15.4	15.9	24.7	8.5	6.6	10.9	8.6	11.1	8.7	11.4	16.9	10.7	19.6	7.9	13.7
pelvis		(15.0-15.7)	(15.6-16.3)	(22.3-27.2)	(7.4-9.5)	(3.5-9.4)	(7.1-16.0)	(6.5-10.6)	(6.6-15.5)	(7.4-10.1)	(7.9-15.3)	(11.1-23.5)	(8.5-12.9)	(15.0-24.6)	(4.7-12.0)	(6.8-21.4)
Brain & CNS	5,725	7.5	8.1	5.0	3.7	3.3	С	3.1	5	6.5	5.6	6.3	4.5	2.7	5.2	2.5
		(7.3-7.7)	(7.9-8.4)	(3.8-6.3)	(2.9-4.4)	(1.3-5.3)		(2.0-4.3)	(2.8-7.2)	(5.3-7.6)	(2.8-8.7)	(3.0-9.7)	(3.4-5.8)	(1.6-4.1)	(1.9-8.8)	(1.0-4.1)
Thyroid	12,370	16.1	14.8	10	21	30.2	10.0	37.3	21.0	19.9	29.7	30.9	20.9	19.5	25.5	34.8
		(15.8-16.5)	(14.5-15.2)	(8.2-11.9)	(19.5-22.7)	(23.4-37.4)	(5.7-14.4)	(32.9-41.7)	(16.5-25.6)	(18.3-21.8)	(23.1-35.8)	(24.4-37.4)	(18.0-23.5)	(16.0-23.0)	(19.0-32.4)	(21.6-48.0)
Hodgkin	2,065	2.8	3.1	1.7	1.4	С	С	1	1.7	2.7	3.7	5.4	3.0	2.8	1.2	1.3
Lymphoma		(2.7-3.0)	(2.9-3.2)	(1.1-2.3)	(1.0-1.9)			(0.4-1.7)	(0.3-3.4)	(2.2-3.3)	(1.5-6.2)	(2.6-8.8)	(1.7-4.0)	(1.2-4.7)	(0.2-2.4)	(0.6-2.1)
Non-Hodgkin	17,940	22.5	23.3	22.8	15.6	11.6	18.4	18.5	14.1	16	16	30.9	20.9	18.9	14.4	12.6
Lymphoma		(22.1-22.8)	(22.9-23.7)	(19.8-25.8)	(13.9-17.0)	(6.9-16.0)	(11.9-25.2)	(15.2-22.1)	(9.9-18.7)	(14.2-17.7)	(10.0-21.6)	(24.5-38.6)	(17.7-23.7)	(13.1-23.7)	(8.5-19.3)	(6.3-19.3)
Multiple	5,745	7.1	7.1	7.8	3.0	1.0	2.9	5.8	4.1	7.8	4.6	15.3	14.1	5.8	9.0	17.5
myeloma		(6.9-7.3)	(6.9-7.4)	(6.2-9.4)	(2.4-3.7)	(0.2-2.0)	(1.0-5.1)	(4.2-7.8)	(2.4-6.2)	(6.5-9.0)	(2.1-7.4)	(10.1-21.0)	(11.8-16.7)	(3.2-8.9)	(4.2-14.0)	(8.2-27.4)
Leukemia	12,010	15.4	16.3	11.2	8.6	2.7	7.3	8.2	7.5	11.1	13.8	12.7	11.2	10.8	7.2	9.3
		(15.1-15.8)	(16.0-16.7)	(9.5-13.0)	(7.4-9.8)	(1.2-4.9)	(4.2-11.4)	(5.7-10.8)	(4.9-10.3)	(9.6-12.6)	(9.2-19.0)	(9.0-17.0)	(8.5-13.5)	(8.0-14.3)	(4.4-10.8)	(3.8-15.2)

95% Cl=confidence intervals based on 2.5th and 97.5th bootstrap percentiles; CNS=central nervous system.

^a Counts are rounded to base 5.

^b Population in this group differs by cancer site; includes individuals not classifiable into other racial categories as described in methods, as well as groups with too few cancer cases to meet disclosure threshold.

^c Number of cases under disclosure threshold, population group was included in 'Other visible minority groups' for this cancer site.

Table 4. Age-standardized incidence rate ratios by cancer site and by race, age-standardized to the Canadian 2011 census population.

rubic 1.7 ige 50			ladia	,	,	, ,		Cauthagat	Courth	Mont			1 -4:	Multiple visible	Other visible
Cancer site	Overall	White	Indigenous peoples	Chinese	Korean	Japanese	Filipino	Southeast Asian	South Asian	West Asian	Arab	Black	Latin American	minority groups	minority groups ^a
All cancers	40/0	1.04	1.03	0.70	0.66	0.80	0.79	0.63	0.58	0.74	0.87	0.88	0.69	0.81	0.77
	1.0 (ref)	(1.04-1.04)	(1.01-1.06)	(0.69-0.71)	(0.61-0.72)	(0.75-0.86)	(0.76-0.82)	(0.59-0.68)	(0.56-0.59)	(0.68-0.78)	(0.81-0.92)	(0.85-0.91)	(0.64-0.73)	(0.75-0.88)	(0.70-0.86)
Head and neck	1.0 (ref)	1.05	1.21	0.80	0.17	0.57	0.69	0.48	0.71	0.62	0.43	0.43	0.52	0.86	0.78
	1.0 (161)	(1.04-1.05)	(1.08-1.36)	(0.71-0.88)	(0.05-0.30)	(0.31-0.86)	(0.53-0.83)	(0.26-0.68)	(0.62-0.81)	(0.40-0.87)	(0.25-0.64)	(0.31-0.56)	(0.33-0.79)	(0.44-1.24)	(0.39-1.21)
Esophagus	1.0 (ref)	1.09	1.16	0.34	b	1.12	0.17	b	0.59	0.45	b	0.53	0.16	b	0.30
	1.0 (161)	(1.07-1.10)	(0.92-1.41)	(0.23-0.43)		(0.39-1.58)	(0.05-0.30)		(0.44-0.78)	(0.12-0.85)		(0.28-0.82)	(0.05-0.35)		(0.14-0.48)
Stomach	1.0 (ref)	0.97	1.20	1.15	3.29	2.81	0.75	1.19	0.64	1.07	1.57	1.30	1.88	1.07	1.17
	1.0 (161)	(0.96-0.98)	(1.02-1.38)	(1.02-1.28)	(2.56-4.03)	(1.97-3.74)	(0.52-0.99)	(0.78-1.60)	(0.51-0.77)	(0.57-1.57)	(1.01-2.14)	(1.00-1.55)	(1.31-2.42)	(0.57-1.58)	(0.63-1.74)
Colorectal	1.0 (ref)	1.04	1.28	0.80	0.66	1.09	0.76	0.69	0.42	0.64	0.76	0.71	0.58	0.83	0.71
	1.0 (161)	(1.04-1.04)	(1.20-1.36)	(0.76-0.85)	(0.53-0.82)	(0.94-1.29)	(0.67-0.86)	(0.56-0.82)	(0.39-0.46)	(0.48-0.78)	(0.61-0.92)	(0.64-0.78)	(0.47-0.70)	(0.65-1.03)	(0.54-0.91)
Anal	1.0 (ref)	1.10	1.05	0.16	b	b	0.64	b	0.39	b	b	0.88	b	b	0.40
	1.0 (161)	(1.08-1.12)	(0.58-1.43)	(0.07-0.26)			(0.22-1.06)		(0.15-0.64)			(0.49-1.32)			(0.19-0.54)
Liver	1.0 (ref)	0.87	2.15	2.52	2.88	0.99	1.46	3.96	0.91	0.51	0.89	1.00	1.38	2.63	0.84
	1.0 (161)	(0.85-0.89)	(1.75-2.56)	(2.27-2.81)	(1.98-3.98)	(0.37-1.68)	(1.10-1.83)	(2.96-4.99)	(0.74-1.13)	(0.19-0.83)	(0.43-1.38)	(0.74-1.29)	(0.76-1.99)	(1.49-3.84)	(0.32-1.51)
Pancreas	1.0 (ref)	1.04	1.15	0.67	0.90	0.87	0.73	0.60	0.56	0.46	0.66	1.07	0.85	0.90	0.44
	1.0 (161)	(1.03-1.05)	(1.00-1.32)	(0.58-0.76)	(0.53-1.33)	(0.56-1.18)	(0.54-0.92)	(0.34-0.86)	(0.47-0.65)	(0.16-0.78)	(0.41-1.01)	(0.84-1.30)	(0.52-1.10)	(0.49-1.32)	(0.10-0.73)
Lung &	1.0 (ref)	1.07	1.36	0.67	0.58	0.53	0.60	0.55	0.21	0.45	0.48	0.41	0.40	0.53	0.41
bronchus	1.0 (161)	(1.06-1.07)	(1.27-1.44)	(0.62-0.71)	(0.46-0.73)	(0.41-0.65)	(0.53-0.67)	(0.42-0.66)	(0.19-0.24)	(0.30-0.58)	(0.37-0.61)	(0.36-0.47)	(0.29 - 0.49)	(0.39-0.67)	(0.24-0.54)
Melanoma	1.0 (ref)	1.19	0.34	0.06	b	b	0.05	0.10	0.06	0.08	0.24	0.17	0.29	0.11	0.06
	1.0 (101)	(1.18-1.19)	(0.28-0.41)	(0.04-0.09)			(0.02-0.08)	(0.03-0.18)	(0.04-0.08)	(0.02-0.15)	(0.13-0.38)	(0.07-0.27)	(0.15-0.40)	(0.02-0.23)	(0.02-0.11)
Breast (female)	1.0 (ref)	1.02	1.00	0.84	0.65	1.12	1.04	0.59	0.77	0.96	1.05	0.80	0.69	1.12	0.86
	1.0 (161)	(1.02-1.03)	(0.93-1.06)	(0.80-0.88)	(0.54-0.78)	(0.97-1.30)	(0.96-1.10)	(0.49-0.72)	(0.72-0.81)	(0.78-1.09)	(0.90-1.21)	(0.73-0.88)	(0.57-0.81)	(0.95-1.30)	(0.68-1.06)
Cervix (female)	1.0 (ref)	1.04	1.61	0.64	0.84	0.93	1.10	1.54	0.66	b	1.50	0.93	1.05	1.32	0.80
	1.0 (101)	(1.02-1.06)	(1.38-1.85)	(0.50-0.78)	(0.41-1.35)	(0.38-1.61)	(0.72-1.39)	(0.93-2.15)	(0.49-0.86)		(0.15-2.48)	(0.63-1.27)	(0.61-1.62)	(0.55-2.13)	(0.28-1.34)
Uterus (female)	1.0 (ref)	1.02	0.74	0.75	0.40	1.03	1.14	0.60	0.94	0.89	0.77	0.88	0.87	1.20	0.67
	1.0 (101)	(1.02-1.03)	(0.65-0.84)	(0.66-0.82)	(0.20-0.61)	(0.71-1.37)	(0.97-1.32)	(0.40-0.83)	(0.85-1.05)	(0.57-1.26)	(0.45-1.11)	(0.73-1.06)	(0.66-1.13)	(0.66-1.81)	(0.41-0.94)
Ovary (female)	1.0 (ref)	1.01	0.95	0.79	0.36	1.60	0.71	1.12	1.07	1.00	0.98	0.82	1.03	0.77	1.30
	1.0 (101)	(1.00-1.03)	(0.78-1.15)	(0.64-0.92)	(0.16-0.60)	(0.92-2.30)	(0.55-0.87)	(0.73-1.56)	(0.91-1.24)	(0.54-1.56)	(0.47-1.50)	(0.61-1.03)	(0.56-1.57)	(0.39-1.19)	(0.39-2.35)
Prostate (male)	1.0 (ref)	1.04	0.83	0.59	0.55	0.82	0.89	0.51	0.57	0.85	0.70	1.91	0.80	0.94	0.94
	1.0 (101)	(1.03-1.04)	(0.77-0.89)	(0.56-0.63)	(0.42-0.69)	(0.67-0.98)	(0.78-0.99)	(0.40-0.63)	(0.53-0.61)	(0.70-1.00)	(0.58-0.82)	(1.79-2.01)	(0.69-0.93)	(0.75-1.16)	(0.73-1.18)
Testis (male)	1.0 (ref)	1.16	0.77	0.36	b	b	0.20	b	0.55	0.98	0.72	0.32	0.75	0.40	0.23
	1.0 (101)	(1.14-1.18)	(0.63-0.97)	(0.25-0.49)			(0.04-0.44)		(0.42-0.70)	(0.31-1.63)	(0.33-1.13)	(0.12-0.50)	(0.44-1.09)	(0.08-0.78)	(0.11-0.38)
Bladder	1.0 (ref)	1.09	0.67	0.40	0.83	0.44	0.36	0.22	0.39	0.78	1.26	0.42	0.37	0.37	0.51
	1.0 (101)	(1.08-1.09)	(0.57-0.76)	(0.35-0.45)	(0.53-1.14)	(0.28-0.61)	(0.25-0.45)	(0.10-0.33)	(0.34-0.45)	(0.53-1.02)	(0.93-1.57)	(0.33-0.52)	(0.22-0.53)	(0.20-0.58)	(0.28-0.77)
Kidney & renal	1.0 (ref)	1.04	1.61	0.55	0.43	0.71	0.56	0.72	0.57	0.74	1.10	0.70	1.27	0.52	0.89
pelvis	1.0 (101)	(1.03-1.04)	(1.46-1.77)	(0.48-0.62)	(0.23-0.61)	(0.46-1.04)	(0.42-0.69)	(0.43-1.01)	(0.48-0.65)	(0.51-0.99)	(0.73-1.53)	(0.56-0.84)	(0.97-1.59)	(0.31-0.77)	(0.44-1.40)

Brain & CNS	1 0 /rof)	1.08	0.66	0.49	0.43	b	0.41	0.67	0.87	0.75	0.84	0.60	0.36	0.69	0.33
	1.0 (ref)	(1.07-1.09)	(0.50-0.85)	(0.39-0.58)	(0.17-0.71)		(0.26-0.57)	(0.37-0.97)	(0.72-1.01)	(0.38-1.17)	(0.41-1.30)	(0.45-0.78)	(0.21-0.55)	(0.26-1.18)	(0.13-0.55)
Thyroid	1.0 (ref)	0.92	0.62	1.30	1.88	0.62	2.32	1.31	1.24	1.84	1.92	1.30	1.21	1.59	2.16
	1.0 (161)	(0.91-0.93)	(0.51-0.74)	(1.21-1.40)	(1.45-2.32)	(0.36-0.90)	(2.05-2.57)	(1.03-1.60)	(1.14-1.35)	(1.44-2.25)	(1.51-2.31)	(1.12-1.45)	(0.99-1.42)	(1.18-2.01)	(1.33-2.96)
Hodgkin	1.0 (ref)	1.08	0.60	0.49	b	b	0.36	0.59	0.95	1.29	1.90	1.05	0.98	0.42	0.47
Lymphoma	1.0 (161)	(1.05-1.10)	(0.42-0.82)	(0.34-0.65)			(0.13-0.60)	(0.11-1.18)	(0.77-1.17)	(0.54-2.17)	(0.93-3.07)	(0.63-1.39)	(0.42-1.67)	(0.05-0.81)	(0.23-0.75)
Non-Hodgkin	1.0 (ref)	1.04	1.01	0.69	0.52	0.82	0.83	0.63	0.71	0.71	1.37	0.93	0.84	0.64	0.56
Lymphoma	1.0 (161)	(1.03-1.04)	(0.88-1.15)	(0.61-0.76)	(0.31-0.71)	(0.53-1.13)	(0.68-0.98)	(0.44-0.83)	(0.64-0.79)	(0.45-0.96)	(1.10-1.72)	(0.79-1.05)	(0.58-1.06)	(0.38-0.86)	(0.28-0.85)
Multiple	1.0 (ref)	1.00	1.11	0.43	0.14	0.41	0.82	0.58	1.09	0.64	2.15	1.98	0.82	1.27	2.47
myeloma	1.0 (161)	(0.99-1.02)	(0.87-1.32)	(0.34-0.52)	(0.03-0.28)	(0.14-0.73)	(0.59-1.10)	(0.33-0.88)	(0.92-1.26)	(0.29-1.05)	(1.43-2.94)	(1.66-2.32)	(0.44-1.27)	(0.60-1.98)	(1.15-3.80)
Leukemia	1 0 (rof)	1.06	0.72	0.56	0.18	0.47	0.53	0.49	0.72	0.90	0.82	0.72	0.70	0.47	0.60
	1.0 (ref)	(1.05-1.07)	(0.62-0.84)	(0.48-0.63)	(0.08-0.32)	(0.27-0.73)	(0.37-0.69)	(0.32-0.67)	(0.62-0.81)	(0.59-1.22)	(0.58-1.11)	(0.55-0.87)	(0.51-0.92)	(0.28-0.69)	(0.24-0.99)

95% CI=confidence intervals based on 2.5th and 97.5th bootstrap percentiles; CNS=central nervous system.

Color coding indicates cells where ratio is significantly higher than 1.0 (Red) or lower than 1.0 (Green).

^a Population in this group differs by cancer site; includes individuals not classifiable into other racial categories as described in methods, as well as groups with too few cancer cases to meet disclosure threshold.

^b Number of cases under disclosure threshold, population group was included in 'Other visible minority groups' for this cancer site.

Table 5. Negative binomial regression cancer incidence rate ratios by race and immigration status, adjusted for age, sex, year, province, and socioeconomic variables.^a

	W	hite	Indigeno	us peoples	East/South	heast Asian	South	n Asian	Middle	Eastern	Bla	ack	Latin A	merican	Other/mu	ltiple visible
															minorit	y groups
	Native-	Foreign-	Native-born	Foreign-	Native-	Foreign-	Native-	Foreign-	Native-	Foreign-	Native-	Foreign-	Native-	Foreign-	Native-	Foreign-
Cancer site	born	born⁵		born ^b	born	born ^b	born	born ^b	born	born ^b	born	born ^b	born	born ^b	born	born⁵
All cancers	1.0 (ref)	0.94	0.96	0.87	0.83	0.68	0.96	0.54	1.27	0.73	0.97	0.79	0.83	0.64	0.96	0.73
		(0.93 - 0.94)	(0.95-0.98)	(0.74-1.03)	(0.79 - 0.87)	(0.67-0.69)	(0.88-1.05)	(0.53-0.56)	(1.10-1.46)	(0.70 - 0.76)	(0.91-1.04)	(0.77 - 0.82)	(0.65-1.06)	(0.61-0.68)	(0.82-1.12)	(0.69-0.77)
Head and neck	1.0 (ref)	0.81	0.96	С	0.90	0.64	1.31	0.58	С	0.43	0.86	0.30	С	0.41	С	0.71
	, ,	(0.76 - 0.85)	(0.88-1.05)		(0.69-1.18)	(0.58-0.70)	(0.80-2.14)	(0.51-0.66)		(0.32 - 0.57)	(0.58-1.28)	(0.23-0.39)		(0.29 - 0.57)		(0.53-0.95)
Esophagus	1.0 (ref)	0.78	0.88	С	0.84	0.22	С	0.43	С	0.29	0.59	0.41	С	0.28	С	0.30
		(0.72 - 0.85)	(0.75-1.04)		(0.51-1.37)	(0.17-0.29)		(0.34-0.55)		(0.16 - 0.54)	(0.24-1.41)	(0.27 - 0.61)		(0.13-0.59)		(0.13-0.66)
Stomach	1.0 (ref)	1.56	1.51	2.33	2.27	1.61	1.17	0.76	2.97	1.37	1.28	1.40	С	1.94	С	1.55
		(1.47-1.65)	(1.35-1.69)	(0.97-5.62)	(1.75-2.95)	(1.46-1.77)	(0.48-2.81)	(0.64-0.90)	(1.24-7.15)	(1.06-1.78)	(0.77-2.12)	(1.15-1.71)		(1.51-2.51)		(1.13-2.14)
Colorectal	1.0 (ref)	0.96	1.25	0.80	1.01	0.80	0.96	0.42	1.48	0.70	1.09	0.69	1.22	0.57	1.18	0.76
		(0.93 - 0.98)	(1.19-1.30)	(0.48-1.33)	(0.88-1.5)	(0.76 - 0.83)	(0.69-1.35)	(0.38 - 0.45)	(0.95-2.29)	(0.62-0.80)	(0.90-1.32)	(0.62-0.76)	(0.58-2.56)	(0.48 - 0.67)	(0.71-1.96)	(0.65-0.89)
Anal	1.0 (ref)	0.91	0.67	С	0.63	0.21	С	0.19	С	0.47	1.37	0.65	С	С	С	С
		(0.79-1.05)	(0.50 - 0.91)		(0.26-1.52)	(0.14-0.31)		(0.11-0.34)		(0.22-0.98)	(0.57-3.30)	(0.40-1.07)				
Liver	1.0 (ref)	0.99	2.11	С	1.70	2.69	С	0.86	С	0.88	1.50	1.06	С	1.16	С	2.19
		(0.90-1.08)	(1.85-2.41)		(1.15-2.51)	(2.44-2.96)		(0.70-1.04)		(0.59-1.31)	(0.83-2.72)	(0.79 - 1.41)		(0.77-1.73)		(1.56-3.06)
Pancreas	1.0 (ref)	0.96	1.03	С	0.92	0.65	0.90	0.53	С	0.51	1.85	0.92	С	0.82	С	0.67
		(0.91-1.02)	(0.93-1.15)		(0.67-1.26)	(0.58-0.72)	(0.37-2.16)	(0.45 - 0.61)		(0.36-0.71)	(1.30-2.63)	(0.76-1.11)		(0.60-1.12)		(0.46-0.98)
Lung &	1.0 (ref)	0.74	1.01	0.89	0.69	0.57	0.61	0.19	1.32	0.37	1.01	0.29	0.97	0.26	0.77	0.38
bronchus		(0.72 - 0.76)	(0.97-1.05)	(0.56-1.41)	(0.59 - 0.82)	(0.54-0.60)	(0.37-1.01)	(0.17-0.21)	(0.82-2.12)	(0.32-0.44)	(0.83-1.23)	(0.25-0.33)	(0.41-2.34)	(0.21-0.32)	(0.39-1.54)	(0.31-0.47)
Melanoma	1.0 (ref)	0.80	0.25	С	0.09	0.05	С	0.04	0.69	0.09	0.13	0.06	С	0.23	С	С
		(0.76 - 0.83)	(0.21-0.29)		(0.05-0.16)	(0.04-0.06)		(0.03-0.05)	(0.31-1.53)	(0.05-0.15)	(0.06-0.27)	(0.04-0.10)		(0.16-0.33)		
Breast (female)	1.0 (ref)	0.96	0.98	0.88	1.01	0.83	0.89	0.76	0.84	1.00	0.84	0.75	С	0.67	1.06	0.96
		(0.94-0.99)	(0.94-1.03)	(0.59-1.30)	(0.90-1.14)	(0.80-0.86)	(0.67-1.17)	(0.72 - 0.80)	(0.49-1.44)	(0.90-1.10)	(0.69-1.02)	(0.69-0.82)		(0.59-0.77)	(0.70-1.62)	(0.85-1.09)
Cervix (female)	1.0 (ref)	0.84	1.43	С	0.84	0.82	0.67	0.55	С	0.21	0.52	0.71	С	0.95	1.32	1.04
		(0.74 - 0.96)	(1.25-1.63)		(0.55-1.30)	(0.70-0.96)	(0.34-1.35)	(0.43-0.70)		(0.10-0.44)	(0.26-1.03)	(0.52-0.99)		(0.65-1.39)	(0.55-3.18)	(0.65-1.65)
Uterus (female)	1.0 (ref)	0.97	0.75	1.16	1.24	0.78	0.74	0.91	С	0.63	0.67	0.80	С	0.93	1.55	0.81
		(0.93-1.02)	(0.68-0.83)	(0.58-2.31)	(0.98-1.58)	(0.72 - 0.84)	(0.35-1.55)	(0.83-1.01)		(0.49 - 0.82)	(0.41-1.07)	(0.68-0.94)		(0.75-1.16)	(0.70-3.45)	(0.62-1.05)
Ovary (female)	1.0 (ref)	1.07	1.14	С	1.29	0.83	1.03	1.04	С	0.92	1.14	0.72	С	0.82	С	0.79
		(1.00-1.15)	(1.00-1.29)		(0.94-1.77)	(0.73-0.93)	(0.53-1.99)	(0.90-1.21)		(0.67-1.26)	(0.71-1.84)	(0.55-0.92)		(0.58-1.17)		(0.53-1.20)
Prostate (male)	1.0 (ref)	0.95	0.82	0.67	0.70	0.61	0.75	0.54	0.66	0.75	1.62	2.01	С	0.84	0.77	0.92
		(0.93-0.97)	(0.78 - 0.87)	(0.37-1.21)	(0.60-0.82)	(0.58-0.64)	(0.46-1.23)	(0.50-0.57)	(0.33-1.31)	(0.67-0.84)	(1.36-1.92)	(1.90-2.13)		(0.73-0.96)	(0.37-1.63)	(0.80-1.05)
Testis (male)	1.0 (ref)	0.99	0.71	С	0.53	0.16	0.98	0.24	С	0.61	0.36	0.14	1.14	0.70	С	0.16
		(0.84-1.16)	(0.58-0.86)		(0.37-0.76)	(0.10-0.24)	(0.70-1.39)	(0.16-0.36)		(0.40 - 0.95)	(0.19-0.69)	(0.06-0.34)	(0.47-2.74)	(0.44-1.14)		(0.04-0.65)
Bladder	1.0 (ref)	0.99	0.51	С	0.51	0.34	0.76	0.35	1.95	0.80	0.61	0.36	С	0.34	С	0.40
		(0.95-1.02)	(0.46-0.57)		(0.38 - 0.69)	(0.31-0.38)	(0.40-1.47)	(0.31-0.40)	(1.05-3.63)	(0.67-0.97)	(0.40-0.94)	(0.29 - 0.44)		(0.24-0.48)		(0.28-0.56)
Kidney & renal	1.0 (ref)	0.96	1.74	1.56	0.88	0.57	0.72	0.58	1.38	0.89	0.90	0.67	С	1.17	С	0.77
pelvis		(0.91-1.01)	(1.62-1.87)	(0.78-3.13)	(0.66-1.17)	(0.51-0.63)	(0.37-1.39)	(0.51-0.66)	(0.62-3.07)	(0.72-1.10)	(0.61-1.33)	(0.55-0.81)		(0.94-1.45)		(0.57-1.05)
Brain & CNS	1.0 (ref)	1.05	0.58	С	0.58	0.46	0.90	0.72	1.01	0.64	0.67	0.55	С	0.37	С	0.65

		(0.97-1.13)	(0.50-0.68)		(0.42-0.81)	(0.39-0.54)	(0.63-1.29)	(0.61-0.85)	(0.50-2.04)	(0.45-0.90)	(0.44-1.04)	(0.41-0.75)		(0.22-0.62)		(0.40-1.04)
Thyroid	1.0 (ref)	1.27	0.66	0.88	1.41	1.75	1.63	1.37	2.63	1.96	0.88	1.26	1.17	1.38	1.92	1.67
		(1.20-1.34)	(0.59-0.74)	(0.36-2.11)	(1.19-1.67)	(1.64-1.87)	(1.30-2.05)	(1.26-1.49)	(1.76-3.92)	(1.72-2.23)	(0.67-1.16)	(1.11-1.43)	(0.58-2.35)	(1.16-1.64)	(1.33-2.76)	(1.38-2.02)
Hodgkin	1.0 (ref)	1.02	0.38	С	0.66	0.30	1.49	0.72	2.05	1.05	0.94	0.71	С	0.44	С	0.87
Lymphoma		(0.88-1.19)	(0.29 - 0.50)		(0.46 - 0.94)	(0.22-0.42)	(1.09-2.03)	(0.55-0.94)	(1.10-3.83)	(0.71-1.56)	(0.61-1.44)	(0.46-1.08)		(0.22-0.89)		(0.45-1.68)
Non-Hodgkin	1.0 (ref)	0.92	0.92	1.28	0.93	0.61	0.84	0.64	1.38	0.91	1.10	0.82	1.37	0.71	0.85	0.47
Lymphoma		(0.88-0.96)	(0.85-1.00)	(0.66-2.46)	(0.76-1.14)	(0.56-0.66)	(0.57-1.23)	(0.58-0.71)	(0.76-2.49)	(0.76-1.08)	(0.83-1.45)	(0.72 - 0.95)	(0.62-3.06)	(0.57-0.89)	(0.42-1.70)	(0.35-0.65)
Multiple	1.0 (ref)	0.98	1.28	С	0.26	0.55	С	0.96	С	1.37	2.11	1.99	С	0.77	С	1.32
myeloma		(0.91-1.05)	(1.12-1.46)		(0.11-0.57)	(0.48 - 0.65)		(0.82-1.12)		(1.04-1.80)	(1.34 - 3.32)	(1.67-2.37)		(0.50-1.18)		(0.92-1.88)
Leukemia	1.0 (ref)	0.96	0.72	1.32	0.78	0.43	0.96	0.62	1.03	0.86	0.72	0.63	1.13	0.75	0.97	0.44
		(0.91-1.01)	(0.65-0.80)	(0.59-2.95)	(0.63-0.98)	(0.38-0.48)	(0.71-1.30)	(0.54-0.70)	(0.58-1.82)	(0.69-1.07)	(0.51-1.02)	(0.1-0.77)	(0.54-2.37)	(0.57-1.00)	(0.55-1.72)	(0.29-0.67)

Cl=confidence interval; CNS=central nervous system. IRR with a p<0.05 highlighted in red and green.

^a Multivariable negative binomial regression model with interaction between race and immigration status, adjusted for age (5-year intervals), sex, diagnosis year (categorical), province of residence, place of residence (rural, urban), education level (not applicable [<15 years], no degree, high school diploma, trades diploma, apprenticeship certificate, college diploma [3-12 month, 1-2 year, >2 year programs], university diploma [below Bachelor level, Bachelor's degree, above Bachelor level, medicine/dentistry/veterinary/optometry degree, Master's degree, Doctorate degree]), and household after-tax income adjusted for household size (quintiles).

^b Foreign-born includes both immigrants and non-permanent residents.

^c Results not disclosed due to low number of cancer events in group (<5).

References

- American Association for Cancer Research. AACR Cancer Disparities Progress Report 2022. 2022. http://www.CancerDisparitiesProgressReport.org/ (accessed Sep 9 2022).
- 2. American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society, 2022.
- 3. McDonald JT, Farnworth M, Liu Z. Cancer and the healthy immigrant effect: a statistical analysis of cancer diagnosis using a linked Census-cancer registry administrative database. *BMC Public Health* 2017; **17**(1): 296.
- 4. Hwee J, Bougie E. Do cancer incidence and mortality rates differ among ethnicities in Canada? *Health Reports* 2021; **32**(8): 3-17.
- 5. Abdel-Rahman O. Patterns and trends of cancer screening in Canada: results from a contemporary national survey. *Journal of the National Comprehensive Cancer Network* 2021; **19**(1): 68-76.
- 6. Withrow DR, Pole JD, Nishri ED, Tjepkema M, Marrett LD. Cancer Survival Disparities Between First Nation and Non-Aboriginal Adults in Canada: Follow-up of the 1991 Census Mortality Cohort. *Cancer Epidemiology, Biomarkers & Prevention* 2017; **26**(1): 145-51.
- 7. Noel CW, Sutradhar R, Li Q, et al. Association of Immigration Status and Chinese and South Asian Ethnicity With Incidence of Head and Neck Cancer. *JAMA Otolaryngology–Head & Neck Surgery* 2020; **146**(12): 1125-35.
- 8. Choi KH, Denice P, Haan M, Zajacova A. Studying the social determinants of COVID-19 in a data vacuum. *Canadian Review of Sociology/Revue canadienne de sociologie* 2021; **58**(2): 146-64.
- 9. Reading CL, Wien F. Health inequalities and the social determinants of Aboriginal peoples' health. 2009.
- 10. Taylor PS. It's Time to Abolish the Absurd (and Slightly Racist) Concept of "Visible Minorities". *C2C Journal*, February 19, 2022, 2022. https://c2cjournal.ca/2022/02/its-time-to-abolish-the-absurd-and-slightly-racist-concept-of-visible-minorities/ (accessed 10/14/2022).
- 11. Canadian Institute for Health Information. Guidance on the Use of Standards for Race-Based and Indigenous Identity Data Collection and Health Reporting in Canada. Ottawa, ON: CIHI, 2022.
- 12. Tjepkema M, Christidis T, Bushnik T, Pinault L. Cohort profile: The Canadian Census Health and Environment Cohorts (CanCHECs). *Health Reports* 2019; **30**(12): 18-26.
- 13. Statistics Canada. 2006 Census of Population. 2007-10-24 https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&ld=30219 (accessed 2022-09-14).
- 14. Statistics Canada. NHS Profile, 2011. 2018-05-24 https://www12.statcan.gc.ca/nhs-enm/2011/dp-pd/prof/index.cfm?Lang=E (accessed 2022-09-14).
- 15. Statistics Canada. Social Data Linkage Environment (SDLE). 2022-08-23. https://www.statcan.gc.ca/en/sdle/index (accessed 2022-09-14).
- Statistics Canada. Canadian Vital Statistics Death database (CVSD). 2022-01-21.
 https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3233 (accessed 2022-09-14).
- 17. Statistics Canada. Canadian Cancer Registry (CCR). 2022-08-22 https://www23.statcan.gc.ca/imdb/p2SV.pl?Function=getSurvey&SDDS=3207 (accessed 2022-09-15).
- 18. Bérard-Chagnon J. Comparison of Place of Residence between the T1 Family File and the Census: Evaluation using record linkage. Ottawa: Statistics Canada, 2017.
- 19. International Agency for Research on Cancer, International Association of Cancer Registries, European Network of Cancer Registries. International rules for multiple primary cancers (ICD-0 third edition). *Eur J Cancer Prev* 2005; **14**(4): 307-8.

- 20. Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2021. Toronto (ON): Canadian Cancer Society, 2021.
- 21. Statistics Canada. Postal Code OM Conversion File Plus (PCCF+). 2022-09-22. https://www150.statcan.gc.ca/n1/en/catalogue/82F0086X (accessed 2022-09-22).
- 22. Statistics Canada. Visible Minority and Population Group Reference Guide, National Household Survey, 2011. 2018-07-25 https://www12.statcan.gc.ca/nhs-enm/2011/ref/guides/99-010-x/99-010-x2011009-eng.cfm (accessed 2022-09-15).
- 23. Statistics Canada. Aboriginal Peoples Reference Guide, National Household Survey, 2011. 2018-07-25 https://www12.statcan.gc.ca/nhs-enm/2011/ref/guides/99-011-x/99-011-x2011006-eng.cfm (accessed 2022-09-15).
- 24. Statistics Canada. Canadian Cancer Registry Age-Standardization: Incidence. 2020-11-23. https://www.statcan.gc.ca/en/statistical-programs/document/3207_D12_V4 (accessed 2022-09-15).
- 25. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. 2019; **144**(8): 1941-53.
- 26. Ferlay J EM, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today. 2020. https://gco.iarc.fr/today (accessed 23 August 2022).
- 27. Alcaraz KI, Wiedt TL, Daniels EC, Yabroff KR, Guerra CE, Wender RC. Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy. *CA: A Cancer Journal for Clinicians* 2020; **70**(1): 31-46.
- 28. Link BG, Phelan J. Social conditions as fundamental causes of disease. *Journal of health and social behavior* 1995: 80-94.
- 29. Gorey KM, Holowaty EJ, Laukkanen E, Fehringer G, Richter NL. Association between socioeconomic status and cancer incidence in Toronto, Ontario: possible confounding of cancer mortality by incidence and survival. *Cancer Prev Control* 1998; **2**(5): 236-41.
- 30. Hajizadeh M, Johnston GM, Manos D. Socio-economic inequalities in lung cancer incidence in Canada, 1992–2010: results from the Canadian Cancer Registry. *Public Health* 2020; **185**: 189-95.
- 31. Decker KM, Lambert P, Bravo J, Demers A, Singh H. Time Trends in Colorectal Cancer Incidence Rates by Income and Age at Diagnosis in Canada From 1992 to 2016. *JAMA Network Open* 2021; **4**(7): e2117556-e.
- 32. Johnson S, McDonald JT, Corsten M, Rourke R. Socio-economic status and head and neck cancer incidence in Canada: A case-control study. *Oral Oncology* 2010; **46**(3): 200-3.
- 33. Phelan JC, Link BG. Is Racism a Fundamental Cause of Inequalities in Health? *Annual Review of Sociology* 2015; **41**(1): 311-30.
- 34. Ferrer AM, Picot G, Riddell WC. New Directions in Immigration Policy: Canada's Evolving Approach to the Selection of Economic Immigrants. *International Migration Review* 2014; **48**(3): 846-67.
- 35. Ng E. The healthy immigrant effect and mortality rates. Health Reports 2011; 22(4): C1.
- 36. Lu C, Ng E. Healthy immigrant effect by immigrant category in Canada. *Health Rep* 2019; **30**(4): 3-11
- 37. Thun MJ, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D. Cancer Epidemiology and Prevention. Fourth edition. ed. New York, NY: Oxford University Press; 2018.
- 38. Poirier AE, Ruan Y, Volesky KD, et al. The current and future burden of cancer attributable to modifiable risk factors in Canada: Summary of results. *Preventive Medicine* 2019; **122**: 140-7.
- 39. Agic B, Mann RE, Tuck A, et al. Alcohol use among immigrants in Ontario, Canada. *Drug and alcohol review* 2016; **35**(2): 196-205.
- 40. Decker KM, Demers AA, Kliewer EV, et al. Pap Test Use and Cervical Cancer Incidence in First Nations Women Living in Manitoba. *Cancer Prevention Research* 2015; **8**(1): 49-55.

- 41. Hamlin-Douglas LK, Coutlée Fo, Roger M, Franco EL, Brassard P. Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in Nunavik, Quebec. *Cancer Epidemiology, Biomarkers & Prevention* 2008; **17**(11): 3141-9.
- 42. Jiang Y, Brassard P, Severini A, et al. Type-specific prevalence of Human Papillomavirus infection among women in the Northwest Territories, Canada. *Journal of Infection and Public Health* 2011; **4**(5): 219-27.
- 43. Wakewich P, Wood B, Davey C, Laframboise A, Zehbe I. Colonial legacy and the experience of First Nations women in cervical cancer screening: a Canadian multi-community study. *Crit Public Health* 2016; **26**(4): 368-80.
- 44. McDonald JT, Kennedy S. Cervical cancer screening by immigrant and minority women in Canada. *Journal of immigrant and minority health* 2007; **9**(4): 323-34.
- 45. Coffin CS, Ramji A, Cooper CL, et al. Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network. *CMAJ Open* 2019; **7**(4): E610.
- 46. Jones N, Chiba N, Fallone C, et al. Helicobacter pylori in First Nations and recent immigrant populations in Canada. *Can J Gastroenterol* 2012; **26**(2): 97-103.
- 47. Fagan-Garcia K, Geary J, Chang H-J, et al. Burden of disease from Helicobacter pylori infection in western Canadian Arctic communities. *BMC Public Health* 2019; **19**(1): 730.
- 48. Uhanova J, Tate RB, Tataryn DJ, Minuk GY. The epidemiology of hepatitis C in a Canadian Indigenous population. *Can J Gastroenterol* 2013; **27**(6): 336-40.
- 49. Biondi MJ, Marchand-Austin A, Cronin K, et al. Prenatal hepatitis B screening, and hepatitis B burden among children, in Ontario: a descriptive study. *Canadian Medical Association Journal* 2020; **192**(43): E1299.
- 50. Sutradhar R, Asidianya N, Lee F, Coburn N, Rabeneck L, Paszat L. Higher risk of gastric cancer among immigrants to Ontario: a population-based matched cohort study with over 2 million individuals. *Gastric Cancer* 2018; **21**(4): 588-97.
- 51. Morais S, Costa AR, Ferro A, Lunet N, Peleteiro B. Contemporary migration patterns in the prevalence of Helicobacter pylori infection: A systematic review. *Helicobacter* 2017; **22**(3): e12372.
- 52. Tsugane S. Salt, salted food intake, and risk of gastric cancer: Epidemiologic evidence. *Cancer Science* 2005; **96**(1): 1-6.
- 53. Weeks KS, Kahl AR, Lynch CF, Charlton ME. Racial/ethnic differences in thyroid cancer incidence in the United States, 2007-2014. *Cancer* 2018; **124**(7): 1483-91.
- 54. Quan H, Fong A, De Coster C, et al. Variation in health services utilization among ethnic populations. *Canadian Medical Association Journal* 2006; **174**(6): 787.
- 55. Mazereeuw MV, Withrow DR, Diane Nishri E, Tjepkema M, Marrett LD. Cancer incidence among First Nations adults in Canada: follow-up of the 1991 Census Mortality Cohort (1992–2009). *Canadian Journal of Public Health* 2018; **109**(5): 700-9.
- 56. Jamal S, Jones C, Walker J, et al. Cancer in First Nations people in Ontario, Canada: Incidence and mortality, 1991 to 2010. *Health Rep* 2021; **32**(6): 14-28.
- 57. Sanou D, O'Reilly E, Ngnie-Teta I, et al. Acculturation and Nutritional Health of Immigrants in Canada: A Scoping Review. *Journal of Immigrant and Minority Health* 2014; **16**(1): 24-34.